Last reviewed · How we verify

Promius Pharma, LLC — Portfolio Competitive Intelligence Brief

Promius Pharma, LLC pipeline: 2 marketed, 0 filed, 1 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 6 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Desonide Cream 0.05% Desonide Cream 0.05% marketed
Cloderm Cream Cloderm Cream marketed Topical corticosteroid Glucocorticoid receptor Dermatology
DFD06 Cream DFD06 Cream phase 3 Topical corticosteroid Glucocorticoid receptor Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 3 shared drug classes
  2. Bausch & Lomb Incorporated · 2 shared drug classes
  3. Ache Laboratorios Farmaceuticos S.A. · 2 shared drug classes
  4. Astellas Pharma Inc · 2 shared drug classes
  5. AstraZeneca · 2 shared drug classes
  6. Eli Lilly and Company · 2 shared drug classes
  7. AO GENERIUM · 2 shared drug classes
  8. Hoffmann-La Roche · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Promius Pharma, LLC:

Cite this brief

Drug Landscape (2026). Promius Pharma, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/promius-pharma-llc. Accessed 2026-06-10.

Related